---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-002165"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2025-01-06T23:59:59+00:00"
generated_at: "2026-05-28T10:34:42.884932+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CytomX to cut ~40% of workforce, focus on CX-2051, extend cash runway

## Summary
- Workforce reduction of ~40%, primarily affecting G&A and non-partnered research staff, substantially complete in Q1 2025.
- Estimated restructuring charges of $5M to $6M, mostly severance, recorded in Q1 2025.
- Cash payments of ~$5M starting Q1 2025; cash runway extended into Q2 2026.
- Company to prioritize CX-2051 (EpCAM PROBODY ADC) and support research collaborations.

## SEC filing metadata
- accession: 0001193125-25-002165
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2025-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000119312525002165/0001193125-25-002165-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000119312525002165/d909597d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-002165
- JSON: https://secwatch.observer/filing/0001193125-25-002165.json
- Plain text: https://secwatch.observer/filing/0001193125-25-002165.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.